Introducing CeO2 nanoparticles for their effect on Nonalcoholic fatty liver disease

The present work introduces CeO2 nanoparticles as an effective agent for Nonalcoholic fatty liver disease therapy. X-ray powder diffraction (XRPD), scanning electron microscopy (SEM), transmission electron microscopy (TEM) and ultraviolet visible (UV-Vis) spectroscopy techniques were used to characterize CeO2 nanoparticles. Patients with acute coronary syndrome (ACS) after stenting were distributed according to the criterion of the presence and absence of concomitant non-alcoholic fatty liver disease (NAFLD), diagnosed by the European Association for the Study with liver fibroelastometry (with the Controlled Attenuation Parameter function). Patients with FATS are distinguished by a longer duration of stay in the intensive care unit as a result of an increase in the incidence of complications of myocardial infarction (p = 0.048). The values of liver fibrosis in steatosis / steatohepatitis in combination with ACS are inversely related to the TIMI (Thrombolysis in Myocardial Infarction) index, and the degree of elevation of transaminases and gamma glutamyltransferase levels exceeds the values in ACS without NAFLD (p <0.05).